news @ Unravel Bio

---

Unravel partners with Spanios Lab to identify novel targets for rare cancer
November 8, 2022
Synergy between Unravel's probabilistic network model of human health and Spanios' patient-derived tumor organoids will unlock a path to efficient discovery of therapeutic targets for rare cancers.

Unravel licenses Wyss Institute at Harvard's technology platform to accelerate CNS drug discovery
September 27, 2022
Unravel has exclusively licensed a patent for treating Rett syndrome and CKDL5 deficiency disorder along with cutting edge CogniXense cognitive screening technology, built on years of DARPA funding. This license will enable Unravel to progress to clinical stage and expand its asset portfolio for indications beyond Rett syndrome.

Unravel partners with TMA Precision Health to advance Rett syndrome therapy to the clinic
July 5, 2022
Unravel has partnered with TMA Precision Health to accelerate clinical translation of its proprietary orla liquid therapeutic for Rett syndrome.

RTK Group announces investment in Unravel Biosciences
June 14, 2022
Expands RTK Group's biopharma investment portfolio into startups developing platform technologies having high potential for disruptive innovation and brings Unravel's innovative patient stratification approach to the forefront of therapeutics discovery.